Featured Research

from universities, journals, and other organizations

Transplantation Does Not Benefit Patients With Refractory Myeloma

Date:
June 7, 2007
Source:
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Summary:
A new study demonstrates that in patients who do not respond to previous chemotherapy procedures, autologous bone-marrow transplantation does not guarantee higher survival rates.

A study, led by Dr. Joan Bladé, researcher of the Haematooncology Group of Hospital Clínic-IDIBAPS (Barcelona), in collaboration with Dr. Laura Rosiñol, researcher of the same group, assessed the efficiency in terms of response and survival of autologous bone marrow transplantation in patients suffering from refractory myeloma previously having undergone high-dose chemotherapy (HDT). Results were conclusive; in patients suffering from resistant myeloma, neither did transplantation show any benefits nor increased survival.

This research work, conducted within the frame of the PETHEMA network, was carried out from October 1999 to December 2000. It was coordinated from Hospital Clínic, Barcelona and had the participation of the six following Spanish hospitals: Hospital Clínico de Salamanca, Hospital de Sant Pau, Hospital Son Dureta Palma de Mallorca, Hospital Universitario de Salamanca, Hospital Ramón y Cajal de Madrid, Hospital La Fe de Valencia. A total of 829 patients under 65 years and suffering from newly diagnosed multiple myeloma underwent 6 chemotherapy treatment cycles.

Firstly, researchers observed that approximately 10% of patients treated with chemotherapy did not respond to the therapy. The group of treated patients suffering from refractory myeloma was divided into two separately investigated subgroups. The first, formed by 62 % of the total number of patients, consisted of refractory patients presenting a stable, non-progressing disease. The second group, the remaining 38%, suffered from progressive disease. Until now, it was believed that the fraction of patients which did not show any response to prior treatment was the most benefited group from subsequent transplantations. Nevertheless, results obtained by this trial unveiled a different idea.

After conducting subsequent autologous bone marrow transplantations in all patients, researchers observed that refractory patients suffering from progressive myeloma did not show any benefit regarding survival. The disease progressed despite of the transplantation. On the other hand, the second group suffering from stable, non-progressive myeloma responded slightly and showed a life time expectancy of 5 more years. This last survival piece of data, a priori interesting, is very similar that obtained from the group of 718 patients which showed response to chemotherapy (HDT). Thus, it still remains to determine whether this improvement of survival in the second group is due to the transplantation, the chemotherapy treatment or to patient's indolent myeloma.

About multiple myeloma

Multiple myeloma is a type of bone marrow cancer, consisting in abnormal proliferation of plasma cells --blood cells producing antibodies that help the body's immune system fight disease. The treatment for this kind of cancer consists of a therapy provoking a decrease in tumour cells previous to successful autologous bone marrow stem cells transplantation.

The pre-transplantation therapy used until now made patients undergo chemotherapy.


Story Source:

The above story is based on materials provided by Institut d'Investigacions Biomèdiques August Pi i Sunyer. Note: Materials may be edited for content and length.


Cite This Page:

Institut d'Investigacions Biomèdiques August Pi i Sunyer. "Transplantation Does Not Benefit Patients With Refractory Myeloma." ScienceDaily. ScienceDaily, 7 June 2007. <www.sciencedaily.com/releases/2007/06/070604123839.htm>.
Institut d'Investigacions Biomèdiques August Pi i Sunyer. (2007, June 7). Transplantation Does Not Benefit Patients With Refractory Myeloma. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2007/06/070604123839.htm
Institut d'Investigacions Biomèdiques August Pi i Sunyer. "Transplantation Does Not Benefit Patients With Refractory Myeloma." ScienceDaily. www.sciencedaily.com/releases/2007/06/070604123839.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) — The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) — The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) — The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) — In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins